XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 154 filers reported holding XENON PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 1.16 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $40,240,548 | -11.3% | 1,178,002 | 0.0% | 1.08% | -0.1% |
Q2 2023 | $45,353,077 | +7.6% | 1,178,002 | 0.0% | 1.08% | +7.3% |
Q1 2023 | $42,160,692 | -9.1% | 1,178,002 | +0.2% | 1.01% | -9.8% |
Q4 2022 | $46,356,747 | +11.1% | 1,175,672 | +1.7% | 1.12% | +3.4% |
Q3 2022 | $41,730,000 | +22.1% | 1,155,961 | +2.9% | 1.08% | +8.3% |
Q2 2022 | $34,180,000 | +32.7% | 1,123,604 | +33.4% | 1.00% | +53.5% |
Q1 2022 | $25,755,000 | +6.9% | 842,498 | +9.2% | 0.65% | +16.3% |
Q4 2021 | $24,098,000 | +170.5% | 771,367 | +32.3% | 0.56% | +197.9% |
Q3 2021 | $8,910,000 | -16.4% | 583,100 | +1.9% | 0.19% | -11.4% |
Q2 2021 | $10,660,000 | +4.0% | 572,500 | 0.0% | 0.21% | -5.8% |
Q1 2021 | $10,248,000 | +29.4% | 572,500 | +11.2% | 0.22% | +33.3% |
Q4 2020 | $7,921,000 | +38.7% | 515,000 | -0.1% | 0.17% | +15.9% |
Q3 2020 | $5,709,000 | -11.7% | 515,711 | 0.0% | 0.14% | -18.1% |
Q2 2020 | $6,467,000 | +14.1% | 515,711 | +3.1% | 0.18% | -24.4% |
Q1 2020 | $5,670,000 | – | 500,000 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 1,594,932 | $48,518,000 | 10.26% |
GREAT POINT PARTNERS LLC | 1,104,334 | $33,594,000 | 8.06% |
ACUTA CAPITAL PARTNERS, LLC | 272,500 | $8,289,000 | 4.62% |
DAFNA Capital Management LLC | 438,623 | $13,343,000 | 3.64% |
Parkman Healthcare Partners LLC | 294,559 | $8,960,000 | 3.30% |
Avoro Capital Advisors LLC | 4,900,000 | $149,058,000 | 2.94% |
Nan Fung Group Holdings Ltd | 114,380 | $3,479,000 | 2.39% |
BVF INC/IL | 1,597,966 | $48,610,000 | 2.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 232,630 | $7,077,000 | 2.18% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 4,391,038 | $133,575,000 | 2.16% |